Role of thalidomide with or without dexamethasone for refractory multiple myeloma;Intérêt du thalidomide avec ou sans dexaméthasone dans le myélome multiple réfractaire

Therapie

Volumn 57, Issue 6, 2002, Pages 524-530

  Boulin, M ^a   Blanchet, F ^a   Isambert, N ^a   Solary, E ^a   Solier, S ^a   Collin, B ^a   Pernot, C ^a   Durnet Archeray, M J ^a  

^a HÔPITAL DU BOCAGE   (France)

Author keywords

Dexamethasone; Multiple myeloma; Thalidomide

Indexed keywords

CYCLOPHOSPHAMIDE; DEXAMETHASONE SODIUM PHOSPHATE; ETOPOFOS; THALIDOMIDE;

ADULT; AGED; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CONSTIPATION; CONTROLLED STUDY; DOSE RESPONSE; DROWSINESS; DRUG TOLERABILITY; FEMALE; HUMAN; MALE; MONOTHERAPY; MULTIPLE MYELOMA; NEUROPATHY; PRIORITY JOURNAL; REVIEW; SURVIVAL TIME;

ADULT; AGED; ANTI-INFLAMMATORY AGENTS; ANTINEOPLASTIC AGENTS; DEXAMETHASONE; DRUG RESISTANCE, NEOPLASM; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; SURVIVAL ANALYSIS; THALIDOMIDE;

EID: 0036869490     PISSN: 00405957     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (32)

1. Solary E. Le myélome multiple. In: Solary E, Belon JP, eds. Thérapeutique pour le pharmacien. Hématologie. Paris: Masson, 1999: 44-8
2. Greenlee RT, Murray T, Bolden S, et al. Cancer statistics 2000. CA Cancer J Clin 2000; 50: 7-33
3. Facon T, Mary JY, Attal M, et al. Melphalan-Prednisone versus Dexamethasone-based regimens for newly diagnosed myeloma patients aged 65-75 years. Safety analysis of the IFM 95 trial on 457 patients. VII International Multiple Myeloma Workshop, Stockholm, 1999
4. Attal M, Harousseau JL, Stoppa A, et al. A prospective, randomised trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. N Engl J Med 1996; 335: 91-7
5. Harousseau JL, Attal M, Payen C, et al. Bone marrow versus blood as source of hematopoietic stem cells after high dose therapy in multiple myeloma: a prospective, randomized study of the Intergroupe Français du Myélome (IFM). Blood 1997; 90(Suppl 1): 231a
6. Sheskin J. Thalidomide in the treatment of lepra reaction. Clin Pharmacol Ther 1965; 6: 303-6
7. Iyer CG, Languillon J, Ramanujam K, et al. VHO co-ordinated short-term double blind trial with thalidomide in the treatment of acute lepra reactions in male lepromatous patients. Bull Wld Hlth Org 1971; 45: 719-32
8. Jacobson JM, Greenspan JS, Spritzler J, et al. Thalidomide for the treatment for oral aphtous ulcers in patients with human immunodeficiency virus infection: National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group. N Engl J Med 1997; 336: 1487-93
9. Stevens RJ, Andujar C, Edwards CJ, et al. Thalidomide in the treatment of cutaneous manifestations of lupus erythematosus: experience in sixteen consecutive patients. Br J Rheumatol 1997; 36: 353-9
10. Duong DJ, Spigel GT, Moxley RT, et al. American experience with low-dose thalidomide therapy for severe cutaneous lupus erythematosus. Arch Dermatol 1999; 135: 1079-87
11. Heney D, Norfolk DR, Wheeldon J, et al. Thalidomide treatment of chronic graft-versus-host disease. Br J Haematol 1991; 78: 23-7
12. Vogelsang GB, Farmer ER, Hess AD, et al. Thalidomide for the treatment of chronic graft-versus-host disease. N Engl J Med 1992; 326: 1055-8
13. Parker PM, Chao N, Nademanee A, et al. Thalidomide as salvage therapy for chronic graft-versus-host disease. Blood 1995; 86: 3604-9
14. D'Amato RJ, Loughnan MS, Flynn E, et al. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci USA 1994; 91: 4082-5
15. Singhal S, Metha J, Desikan R, et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 1999; 341: 1565-71
16. Kneller A, Raanani P, Hardan I, et al. Therapy with thalidomide in refractory multiple myeloma patients-the revival of an old drug. Br J Haematol 2000; 108: 391-3
17. Juliusson G, Celsing F, Turesson I, et al. Frequent good partial remissions from thalidomide including best response ever in patients with advanced refractory and relapsed myeloma. Br J Haematol 2000; 109: 89-96
18. Rajkumar V, Fonseca R, Dispenzieri A, et al. Thalidomide in the treatment of relapsed multiple myeloma. Mayo Clin Proc 2000; 75: 897-901
19. Yakoub-Agha I, Moreau P, Levraz S, et al. Thalidomide in patients with advanced myeloma. Hematol J 2000; 1: 186-9
20. Barlogie B, Desikan R, Eddlemon P, et al. Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients. Blood 2001; 98: 492-4
21. Hus M, Dmoszynska A, Soroka-Wojtaszko M, et al. Thalidomide treatment of resistant or relapsed multiple myeloma patients. Haematologica 2001; 86: 404-8
22. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-81
23. Vacca A, Ribatti D, Roncali L, et al. Bone marrow angiogenesis and progression in multiple myeloma. Br J Haematol 1994; 87: 503-8
24. Vacca A, Ribatti D, Presta M, et al. Bone marrow neovascularization, plasma cell angiogenic potential, and matrix metalloproteinase-2 secretion parallel progression of human multiple myeloma. Blood 1999; 93: 3064-73
25. Geitz H, Handt S, Zwingenberger K, et al. Thalidomide selectively modulates the density of cell surface molecules involved in the adhesion cascade. Immunopharmacol 1996; 31: 213-21
26. Sampaio EP, Sarno EN, Galilly R, et al. Thalidomide selectively inhibits tumor necrosis factor a production by stimulated human monocytes. J Exp Med 1991; 173: 699-703
27. Moreira AL, Sampaio EP, Zmuidzinas A, et al. Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation. J Exp Med 1993; 177: 1675-80
28. Moller DR, Wysocka M, Greenlee BM, et al. Inhibition of IL-12 production by thalidomide. J Immunol 1997; 159: 5157-61
29. Haslett PA, Corral LG, Albert M, et al. Thalidomide costimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production, and cytotoxic responses in the CD8+ subset. J Exp Med 1998; 187: 1885-92
30. Davies FE, Raje N, Hideshima T, et al. Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. Blood 2001; 98: 210-6
31. Hideshima T, Chauhan D, Shima Y, et al. Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy. Blood 2000; 96: 2943-50
32. Weber DM, Gavino M, Delasalle K, et al. Thalidomide alone or with dexamethasone for multiple myeloma. Blood 1999; 94(Suppl 1): 604a